Skip to main content

Table 3 Monthly migraine days, monthly headache days, and monthly days with acute medication use across the observation period in patients with episodic migraine and patients with chronic migraine

From: Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience

Patients with episodic migraine (n=14)

 

Baseline

Last treatment month

3 months after discontinuation

3 months after restart

Monthly migraine days

8.4 ± 2.9

4.6 ± 3.6

7.8 ± 4.2

4.7 ± 3.3

Monthly headache days

8.9 ± 3.4

5.1 ± 4.2

8.4 ± 4.3

4.9 ± 3.2

Monthly days with acute medication use

7.3 ± 4.1

4.1 ± 3.4

6.6 ± 3.0

3.8 ± 3.0

Patients with chronic migraine (n=25)

 

Baseline

Last treatment month

3 months after discontinuation

3 months after restart

Monthly migraine days

14.4 ± 5.3

9.1 ± 5.4

14.8 ± 5.8

9.5 ± 5.8

Monthly headache days

16.6 ± 6.0

9.1 ± 5.3

15.2 ± 5.5

9.8 ± 5.6

Monthly days with acute medication use

13.1 ± 5.3

6.9 ± 5.0

11.3 ± 5.5

6.8 ± 5.1

  1. Values are mean ± standard deviation (descriptive values, statistical significance is not provided)